Comparison of Radiolableled Somatostatin Analogues and (131) I-MIBG Treatment for the Management of Patients with Metastatic/Progressive Phaeochromocytomas and Paragangliomas
#941
Introduction: Radionuclide therapy has been used to treat patients with progressive/metastatic paragangliomas (PGGs) and pheochromocytomas (PCCs). To date, there is no study comparing (131)I-MIBG and peptide receptor radionuclide treatment (PRRT) in those patients.
Aim(s): To compare the effectiveness of those modalities in progressive PCCs and PGGs.
Materials and methods: All patients had progressive tumors, despite previous treatments. Overall survival (OS), progression-free survival (PFS), event-free survival (EFS) and response to treatment were calculated. Renal and hematological toxicity were documented.
Conference: 11th Annual ENETSConcerence (2014)
Presenting Author:
Authors: Nastos K, Toumpanakis C, Cheung V, Navalkissoor S, Quigley A,
Keywords: paraganglioma, pheochromocytoma, (131)I-MIBG, PRRT,
To read the full abstract, please log into your ENETS Member account.